What do systematic reviews say?

Intervention not reported

• Non‐pharmacological measures implemented in the setting of long‐term care facilities to prevent SARS‐CoV‐2 infections… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Intervention not reported

• Non‐pharmacological measures implemented in the setting of long‐term care facilities to prevent SARS‐CoV‐2 infections… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Intervention not reported

• Non‐pharmacological measures implemented in the setting of long‐term care facilities to prevent SARS‐CoV‐2 infections… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Intervention not reported

• Non‐pharmacological measures implemented in the setting of long‐term care facilities to prevent SARS‐CoV‐2 infections… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Intervention not reported

• Non‐pharmacological measures implemented in the setting of long‐term care facilities to prevent SARS‐CoV‐2 infections… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Intervention not reported

• Non‐pharmacological measures implemented in the setting of long‐term care facilities to prevent SARS‐CoV‐2 infections… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Intervention not reported

• Non‐pharmacological measures implemented in the setting of long‐term care facilities to prevent SARS‐CoV‐2 infections… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Intervention not reported

• Non‐pharmacological measures implemented in the setting of long‐term care facilities to prevent SARS‐CoV‐2 infections… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Intervention not reported

• Non‐pharmacological measures implemented in the setting of long‐term care facilities to prevent SARS‐CoV‐2 infections… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Intervention not reported

• Non‐pharmacological measures implemented in the setting of long‐term care facilities to prevent SARS‐CoV‐2 infections… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Intervention not reported

• Non‐pharmacological measures implemented in the setting of long‐term care facilities to prevent SARS‐CoV‐2 infections… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Intervention not reported

• Non‐pharmacological measures implemented in the setting of long‐term care facilities to prevent SARS‐CoV‐2 infections… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Intervention not reported

• Non‐pharmacological measures implemented in the setting of long‐term care facilities to prevent SARS‐CoV‐2 infections… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Insulin glargine vs NPH insulin

It is very uncertain whether insulin glargine changes diabetes‐related complications (1) Fatal MI (2) Fatal stroke (3)… compared with NPH insulin (very low certainty).

• (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
  RR 1.03 [0.6, 1.77]
  1 study · 4 participants
  Very low

Summary of findings: insulin detemir vs NPH insulin

Insulin detemir showed no clear difference in AEs other than hypoglycaemia (1) SAE (2) Overall AE (3) AE leading… compared with NPH insulin (moderate certainty).

• (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
  RR 0.88 [0.64, 1.2]
  1 study · 8 participants
  Moderate

Summary of findings: insulin detemir vs NPH insulin

The review found no eligible studies for this question.

• (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Insulin glargine vs NPH insulin

It is very uncertain whether insulin glargine changes hypoglycaemic episodes(1) Severe hypoglycaemia (2) Serious… compared with NPH insulin (very low certainty).

• (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
  RR 0.68 [0.46, 1.01]
  1 study · 14 participants
  Very low

Insulin glargine vs NPH insulin

• (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1228 participants
  Very low

Insulin glargine vs NPH insulin

Insulin glargine showed no clear difference in AEs other than hypoglycaemia (1) SAE (2) Overall AE (3) AE leading… compared with NPH insulin (moderate certainty).

• (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
  RR 0.98 [0.87, 1.1]
  1 study · 13 participants
  Moderate

Insulin glargine vs NPH insulin

The review found no eligible studies for this question.

• (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found